Observational studyJournal for immunotherapy of cancer2021
Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study.
Observational study in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Balancing immunosuppression and cancer survival in the treatment of immune checkpoint inhibitor-associated inflammatory arthritis.EULAR rheumatology open · 2026Review
- Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis.The Journal of rheumatology · 2026Article
- The management of rheumatic immune related adverse events.Best practice & research. Clinical rheumatology · 2026Review
- The association of osteoarthritis with the risk of de novo inflammatory arthritis in patients receiving immune checkpoint inhibitors: a retrospective study.medRxiv : the preprint server for health sciences · 2026Article
- Understanding the Inflammatory Aspect of Osteoarthritis: Lessons from Immune Checkpoint Inhibitors.Journal of clinical medicine · 2026Review
- Immune checkpoint inhibitor-related arthritis and oral disorders: shared pathophysiology and clinical implications for rheumatology and oral health.Cancer cell international · 2025Review
- Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells.Journal for immunotherapy of cancer · 2025Article
- Assessing the effects of immune checkpoint inhibitors on bone utilizing machine learning-assisted opportunistic quantitative computed tomography.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025Article
- The Bidirectional Role of Obesity and Aging in the Pathogenesis of Osteoarthritis: Molecular Mechanisms, Epigenetic Insights, and Therapeutic Implications.Journal of inflammation research · 2025Review
- Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy.Expert review of clinical immunology · 2024Review
- Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management.Rheumatic diseases clinics of North America · 2024Review
- Rapid onset pembrolizumab-induced inflammatory arthritis diagnosed using musculoskeletal ultrasound.BMJ case reports · 2024Article
- PD-L1/PD-1 pathway: a potential neuroimmune target for pain relief.Cell & bioscience · 2024Review
- Advances of autoimmune rheumatic diseases related to malignant tumors.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Review
- Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study.The oncologist · 2023Article
- Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study.Frontiers in pharmacology · 2023Article
- Treatment of rheumatic adverse events of cancer immunotherapy.Best practice & research. Clinical rheumatology · 2022Review
- Monitoring and Management of the Patient with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Current Perspectives.Journal of inflammation research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can result in toxicities, known as immune-related adverse events (irAEs), due to a hyperactivated immune system. ICI-related inflammatory arthritis has been described in literature, but herewith we introduce and characterize post-ICI-activated osteoarthritis (ICI-aOA). We conducted a multicenter, retrospective, observational study of patients with cancer treated with ICIs and diagnosed with ICI-aOA by a rheumatologist. ICI-aOA was defined by (1) an increase in non-inflammatory joint pain after ICI initiation, (2) in joints characteristically affected by osteoarthritis, and (3) lack of inflammation on exam. Cases were graded using the Common Terminology Criteria for Adverse Events (CTCAE) V.6.0 rubric for arthralgia. Response Evaluation Criteria in Solid Tumors V.1.1 (v.4.03) guidelines determined tumor response. Results were analyzed using χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.